vimarsana.com

Page 5 - பத்திரங்கள் மோசடி நடவடிக்கை News Today : Breaking News, Live Updates & Top Stories | Vimarsana

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Acadia Pharmaceuticals (ACAD) Investors with Losses to Contact Its Attorneys Now, Securities Fraud Class Action Filed

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Acadia Pharmaceuticals (ACAD) Investors with Losses to Contact Its Attorneys Now, Securities Fraud Class Action Filed News provided by Share this article Class Period: June 15, 2020 - Apr. 4, 2021 Lead Plaintiff Deadline: June 18, 2021                                                Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) Securities Fraud Action: The complaint alleges that Defendants misrepresented facts concerning Acadia s supplemental new drug application ( sNDA ) for NUPLAZID® (pimavanserin), which treats dementia-related psychosis ( DRP ). Specifically, on July 20, 2020, Acadia announced the FDA accepted for filing the sNDA and stated that its pivotal study for the drug showed a meaningful reduction of psychosis symptoms and a nearly 3X reduction in the risk of relapse for patients continuing on pimavanserin vs. placebo.  Thereafter, the company repeatedly stated the FDA h

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Romeo Power (RMO) Investors with Losses to Contact Its Attorneys Now, Securities Fraud Class Action Filed

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Romeo Power (RMO) Investors with Losses to Contact Its Attorneys Now, Securities Fraud Class Action Filed News provided by Share this article SAN FRANCISCO, April 21, 2021 /PRNewswire/ Hagens Berman urges Romeo Power, Inc. (NYSE: RMO) investors with significant losses to submit your losses now. A securities class action has been filed and certain investors may have valuable claims. Class Period: Oct. 5, 2020 - Mar. 30, 2021 Lead Plaintiff Deadline: June 15, 2021                                               Romeo Power, Inc. (NYSE: RMO) Securities Fraud Action: The complaint centers on Romeo s misrepresentations and omissions concerning its access to battery cells, a key component of the company s battery modules and packs.

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Canaan (CAN) Investors with Losses to Contact Its Attorneys Now, Securities Fraud Case Filed

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Canaan (CAN) Investors with Losses to Contact Its Attorneys Now, Securities Fraud Case Filed News provided by Share this article SAN FRANSISCO, April 19, 2021 /PRNewswire/ Hagens Berman urges Canaan Inc.  (NASDAQ: CAN) investors with significant losses to submit your losses now. A securities class action has been filed and certain investors may have valuable claims. Class Period: Feb. 10, 2021 – Apr. 9, 2021 Lead Plaintiff Deadline: June 14, 2021                                               The complaint is focused on Canaan s statements about its bitcoin mining machine business. According to the complaint, in past months, Canaan has falsely touted substantial improvement in its revenue visibility, its ability to more precisely forecast revenues, and its receipt of larger orders for its bitcoin mining machines. As recently as Apr. 9, 2021, Canaan s CEO reportedly assured

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages FibroGen (FGEN) Investors with Losses to Contact Its Attorneys Now, Securities Fraud Class Action Filed and Investor Deadline Established

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages FibroGen (FGEN) Investors with Losses to Contact Its Attorneys Now, Securities Fraud Class Action Filed and Investor Deadline Established News provided by Share this article Class Period: Nov. 8, 2019 – Apr. 6, 2021 Lead Plaintiff Deadline: June 11, 2021                                                Securities Fraud Action: The complaint centers on FibroGen s presentation of false data of roxadustat to make the anemia drug look safer than it is. Throughout the Class Period, FibroGen touted the prospects of roxadustat. A key selling point for the drug was its purported heart safety as compared to standard of care erythropoietin (EPO) injectable therapies, which cannot be proscribed to a variety of patients at risk of major cardiac events. To support this marketing edge, FibroGen presented data from phase 3 trials purportedly showing roxadustat was safer than EPO, among other a

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.